Aldatu Biosciences

Aldatu Biosciences is making a significant impact in the biotechnology and healthcare industries, with its groundbreaking diagnostic solutions for infectious diseases. The company's proprietary PANDAA technology, which is a qPCR-enabling platform, has enabled Aldatu to overcome long-standing diagnostic challenges, thereby enhancing the quality and affordability of high-throughput infectious disease diagnostics. This innovation has also resulted in improved patient access to diagnostics, particularly in resource-limited countries. Moreover, the PANDAA qDx™ SARS-CoV-2 assay developed by Aldatu Biosciences is already being implemented in numerous clinical labs. The company's commitment to addressing the pressing need for COVID-19 testing is evident from the establishment of Aldatu Diagnostics, a clinical lab dedicated to utilizing the PANDAA technology for this purpose. Founded in 2014 and headquartered in the United States, the company has recently received a significant $3.00M grant investment on 12 September 2022 from the National Institute of Allergy and Infectious Diseases. Aldatu Biosciences has firmly positioned itself as a leader in adaptive diagnostics, reflecting its dedication to advancing global health responses through cutting-edge innovation and accessibility.